


Amendment to the Claims:

Cancel Claims 18-21.

Listing of Claims:


1. (original): A compound of structural formula I:



or a pharmaceutically acceptable salt thereof; wherein

n is 0, 1, or 2;

B is



X is CH₂, CHF, CF₂, or C=CH₂;

Y is N or C-R⁹;

W is O or S;

R¹ is C₂₋₄ alkenyl, C₂₋₄ alkynyl, or C₁₋₄ alkyl, wherein alkyl is unsubstituted or substituted with hydroxy, amino, C₁₋₄ alkoxy, C₁₋₄ alkylthio, or one to three fluorine atoms;

R² is hydrogen, fluorine, amino, hydroxy, mercapto, C₁₋₄ alkoxy, C₁₋₈ alkylcarbonyloxy, or C₁₋₄ alkyl;


R³ and R⁴ are each independently selected from the group consisting of hydrogen, cyano, azido, halogen, hydroxy, mercapto, amino, C₁₋₄ alkoxy, C₁₋₈ alkylcarbonyloxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, and C₁₋₄ alkyl, wherein alkyl is unsubstituted or substituted with hydroxy, amino, C₁₋₄ alkoxy, C₁₋₄ alkylthio, or one to three fluorine atoms;

R⁵ is hydrogen, C₁₋₁₀ alkylcarbonyl, P₃O₉H₄, P₂O₆H₃, or P(O)R¹³R¹⁴;


R⁶ and R⁷ are each independently hydrogen, methyl, hydroxymethyl, or fluoromethyl;

X is CH₂; Y is N; R¹⁰ is NH₂; R² and R³ are α-OH; and R⁴, R⁵, R⁶, R⁷, R⁸, and R¹¹ are hydrogen, then R¹ is not β-methyl.

2. (original): The compound of Claim 1 wherein B is



3. (original): The compound of Claim 2 of structural formula II:



wherein

R¹ is C₁₋₃ alkyl, wherein alkyl is unsubstituted or substituted with one to three fluorine atoms;

R² is hydroxy, fluoro, C₁₋₃ alkoxy, or C₁₋₈ alkylcarbonyloxy;

R³ is hydrogen, halogen, hydroxy, amino, C₁₋₃ alkoxy, or C₁₋₈ alkylcarbonyloxy;

R⁵ is hydrogen, C₁₋₈ alkylcarbonyl, P₃O₉H₄, P₂O₆H₃, or PO₃H₂;

R⁸ is hydrogen, amino, or C₁₋₄ alkylamino; and

R¹⁰ and R¹¹ are each independently hydrogen, halogen, hydroxy, amino,

C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, or C₃₋₆ cycloalkylamino;

with the proviso that when R¹⁰ is NH₂, R² and R³ are α-OH, and R⁵, R⁸, and R¹¹ are hydrogen, then R¹ is not β-methyl.

4. (original): The compound of Claim 3 wherein

R¹ is methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R² is hydroxy, fluoro, or methoxy;

R³ is hydrogen, fluoro, hydroxy, amino, or methoxy;


R⁵ is hydrogen or P₃O₉H₄;

R⁸ is hydrogen or amino; and

R¹⁰ and R¹¹ are each independently hydrogen, fluoro, hydroxy, or amino;

with the proviso that when R¹⁰ is NH₂, R² and R³ are α-OH, and R⁵, R⁸, and R¹¹ are hydrogen, then R¹ is not β-methyl.

5. (original): The compound of Claim 2 of structural formula III:



wherein

R¹ is C₁₋₃ alkyl, wherein alkyl is unsubstituted or substituted with one to three fluorine atoms;

R² is hydroxy, fluoro, C₁₋₃ alkoxy, or C₁₋₈ alkylcarbonyloxy;

R³ is hydrogen, halogen, hydroxy, amino, C₁₋₃ alkoxy, or C₁₋₈ alkylcarbonyloxy;

R⁵ is hydrogen, C₁₋₈ alkylcarbonyl, P₃O₉H₄, P₂O₆H₃, or PO₃H₂;

R⁸ is hydrogen, amino, or C₁₋₄ alkylamino;

R⁹ is hydrogen, cyano, methyl, halogen, CONH₂ or CSNH₂; and

R¹⁰ and R¹¹ are each independently hydrogen, halogen, hydroxy, amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, or C₃₋₆ cycloalkylamino.

6. (original): The compound of Claim 5 wherein

R¹ is methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R² is hydroxy, fluoro, or methoxy;

R³ is hydrogen, fluoro, hydroxy, amino, or methoxy;


R⁵ is hydrogen or P₃O₉H₄;

R⁸ is hydrogen or amino;

R⁹ is hydrogen, cyano, methyl, halogen, CONH₂ or CSNH₂; and

R¹⁰ and R¹¹ are each independently hydrogen, fluoro, hydroxy, or amino.

7. (original): The compound of Claim 2 of structural formula IV:



(IV)

wherein

R¹ is C₁₋₃ alkyl, wherein alkyl is unsubstituted or substituted with one to three fluorine atoms;

R² is hydroxy, fluoro, C₁₋₃ alkoxy, or C₁₋₈ alkylcarbonyloxy;

R³ is hydrogen, halogen, hydroxy, amino, C₁₋₃ alkoxy, or C₁₋₈ alkylcarbonyloxy;

R⁵ is hydrogen, C₁₋₈ alkylcarbonyl, P₃O₉H₄, P₂O₆H₃, or PO₃H₂;

R⁸ is hydrogen, amino, or C₁₋₄ alkylamino; and

R¹⁰ and R¹¹ are each independently hydrogen, halogen, hydroxy, amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, or C₃₋₆ cycloalkylamino.

8. (original): The compound of Claim 7 wherein

R¹ is methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R² is hydroxy, fluoro, or methoxy;


R³ is hydrogen, fluoro, hydroxy, amino, or methoxy;

R⁵ is hydrogen or P₃O₉H₄;

R⁸ is hydrogen or amino; and

R¹⁰ and R¹¹ are each independently hydrogen, fluoro, hydroxy, or amino.

9. (original): The compound of Claim 2 of structural formula V:



(V)

wherein

R¹ is C₁₋₃ alkyl, wherein alkyl is unsubstituted or substituted with one to three fluorine atoms;

R² is hydroxy, fluoro, C₁₋₃ alkoxy, or C₁₋₈ alkylcarbonyloxy;

R³ is hydrogen, halogen, hydroxy, amino, C₁₋₃ alkoxy, or C₁₋₈ alkylcarbonyloxy;

R⁵ is hydrogen, C₁₋₈ alkylcarbonyl, P₃O₉H₄, P₂O₆H₃, or PO₃H₂;

R⁸ is hydrogen, amino, or C₁₋₄ alkylamino;

R⁹ is hydrogen, cyano, methyl, halogen, CONH₂ or CSNH₂; and

R¹⁰ and R¹¹ are each independently hydrogen, halogen, hydroxy, amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, or C₃₋₆ cycloalkylamino.

10. (original): The compound of Claim 9 wherein

R¹ is methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;

R² is hydroxy, fluoro, or methoxy;

R³ is hydrogen, fluoro, hydroxy, amino, or methoxy;

R⁵ is hydrogen or P₃O₉H₄;

R⁸ is hydrogen or amino;

R⁹ is hydrogen, cyano, methyl, halogen, CONH₂ or CSNH₂; and

R¹⁰ and R¹¹ are each independently hydrogen, fluoro, hydroxy, or amino.

11. (original): The compound of Claim 2 selected from the group consisting of:

2-amino-7-[(1 β ,2 α OH,3 α ,4 β)-2,3-dihydroxy-4-hydroxymethyl-2-methyl-5-methylenecyclopentyl]-3,7-dihydro-4*H*-pyrrolo[2,3-*d*]pyrimidin-4-one;

2-amino-7-[(1*R*,2*S*,3*R*,4*R*)-2,3-dihydroxy-4-hydroxymethyl-2-methyl-5-methylenecyclopentyl]-3,7-dihydro-4*H*-pyrrolo[2,3-*d*]pyrimidin-4-one;

(1 α OH,2 α ,3 β ,5 β)-5-(4-amino-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-3-hydroxymethyl-1-methyl-4-methylenecyclopentane-1,2-diol;

(1*S*,2*R*,3*R*,5*R*)-5-(4-amino-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-3-hydroxymethyl-1-methyl-4-methylenecyclopentane-1,2-diol;

(1 β ,2 α OH,3 α ,4 β)-2-amino-9-[2,3-dihydroxy-4-(hydroxymethyl)-2-methyl-5-methylenecyclopentyl]-1,9-dihydro-6*H*-purin-6-one;

2-amino-9-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-2-methyl-5-methylenecyclopentyl]-1,9-dihydro-6*H*-purin-6-one;

(1S,2R,3R,5R)-5-(6-amino-9*H*-purin-9-yl)-3-(hydroxymethyl)-1-methyl-4-methylenecyclopentane-1,2-diol;

(1 α OH,2 α ,3 β ,5 β)-5-(6-amino-9*H*-purin-9-yl)-3-(hydroxymethyl)-1-methyl-4-methylenecyclopentane-1,2-diol;

(1RS,2R,3R,5R)-5-(4-amino-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-3-(hydroxymethyl)-1-methylcyclopentane-1,2-diol;

(1S,2R,3R,5R)-5-(4-amino-7*H*-pyrrolo[2,3-*d*]pyrimidin-7-yl)-3-(hydroxymethyl)-1-methylcyclopentane-1,2-diol;

(1RS,2R,3R,5R)-5-(6-amino-9*H*-purin-9-yl)-3-(hydroxymethyl)-1-methylcyclopentane-1,2-diol;

(1S,2R,3R,5R)-5-(6-amino-9*H*-purin-9-yl)-3-(hydroxymethyl)-1-methylcyclopentane-1,2-diol;

2-amino-9-[(1R,2RS,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-2-methylcyclopentyl]-1,9-dihydro-6*H*-purin-6-one;

2-amino-9-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-2-methylcyclopentyl]-1,9-dihydro-6*H*-purin-6-one;

2-amino-7-[(1R,2RS,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-2-methylcyclopentyl]-3,7-dihydro-4*H*-pyrrolo[2,3-*d*]pyrimidin-4-one; and

2-amino-7-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)-2-methylcyclopentyl]-3,7-dihydro-4*H*-pyrrolo[2,3-*d*]pyrimidin-4-one;

and the corresponding 5'-triphosphates;
or a pharmaceutically acceptable salt thereof

12. (original): A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

13. (original): A method of treating RNA-dependent RNA virus infection comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to Claim 1.

14. (original): The method of Claim 13 wherein said RNA-dependent RNA virus infection is a hepatitis C virus (HCV) infection.

15. (original): The method of Claim 14 in combination with a therapeutically effective amount of another agent active against HCV.

16. (original): The method of Claim 15 wherein said agent active against HCV is a 2'-C-Me-ribonucleoside; ribavirin; levovirin; thymosin alpha-1; interferon- β ; an inhibitor of NS3 serine protease; an inhibitor of inosine monophosphate dehydrogenase; interferon- α or pegylated interferon- α , alone or in combination with ribavirin or levovirin.

17. (original): The method of Claim 16 wherein said agent active against HCV is interferon- α or pegylated interferon- α , alone or in combination with ribavirin.

18. (cancelled)

19. (cancelled)

20. (cancelled)

21. (cancelled)